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The Guild’s proposals for the Pharmaceutical 
Strategy for Europe
Background 
The European Union is in the process of 
launching a novel strategy to improve patients’ 
access to medicines and to support innovation 
in the pharmaceutical industry of the EU 
(“Pharmaceutical Strategy for Europe”). Within 
this framework, one objective is to address how 
scientific and technological advances are put 
into practice. Among preclinical and clinical in-
vestigators it has long been recognised that it 
is extremely difficult to pursue industry-inde-
pendent, multinational clinical studies1. These 
are of paramount importance for investigating 
the safety and efficacy of drugs and interven-
tions, and for supporting more personalised 
decision-making in health care. The covid-19-
pandemic has even further highlighted the  
 
1 We refer here to the definition of clinical studies provided by 
the European Commission: “A ‘clinical study’ is defined as any 
clinical research involving a substantial amount of work related 
to the observation of, data collection from, or diagnostic or 
therapeutic intervention on multiple or individual patients. It 
 
challenges in initiating, coordinating and eval-
uating multinational studies within the EU. This 
is mainly due to three reasons: 
1. For some innovative treatments there is no 
interest among industrial shareholders to 
develop or evaluate new strategies. 
2. The existing regulatory framework, both at 
a national and European level, is not 
aligned with the rapidly developing inno-
vations in medicine. 
3. There is no dedicated framework for inter-
national, multicenter clinical studies within 
the current and upcoming EU Framework 
includes but is not limited to clinical trials in the sense of the 
EU Clinical Trials Directive (2001/20/EU)”: https://ec.eu-
ropa.eu/research/participants/data/ref/h2020/other/le-
gal/templ/h2020_tmpl-clinical-studies_2018-2020_en.pdf 
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Programme for Research and Innovation 
(Horizon 2020 and Horizon Europe). 
The above-mentioned challenges apply to 
studies on pharmaceuticals, medical devices, 
and advanced therapies. 
The Pharmaceutical Strategy for Europe repre-
sents an opportunity to develop a European 
Framework for Multinational Clinical Studies -
“EU-CLIN”. Such a framework, coupled with 
appropriate research funding in this area under 
Horizon Europe, would help to tackle existing 
unmet needs and to foster cutting-edge bio-
medical and clinical research, which is a crucial 
stage of the life cycle of medicines and para-
mount to boosting Europe’s competitiveness.  
While addressing clinical studies, the proposed 
framework would need to take into account the 
specific obstacles for clinical trials. When com-
pared to for example collecting real world 
data, clinical trials are strongly regulated and 
require a specific approval process through the 
current Voluntary Harmonization Procedure as 
well as the upcoming European Clinical Trials 
Regulation, registration in EudraCT, access to 
Eudravigilance, and good clinical practice 
monitoring. Once it will become applicable, 
the European Clinical Trials Regulation (EU No 
536/2014), will simplify and harmonise the ad-
ministrative provisions governing clinical trials. 
The proposed EU-CLIN framework, together 
with targeted investment to support capacities 
and innovation in academia, would be instru-
mental for the successful implementation of 
the Regulation in independent clinical re-
search.    
In this paper we provide an overview of the ex-
isting barriers and concrete actions that, if im-
plemented in the context of the Pharmaceuti-
cal Strategy for Europe, will effectively support 
 
2 https://www.ukbiobank.ac.uk/ 
research and innovation focusing on medicines 
and diagnostics for the benefit of patients and 
our societies.  
Existing unmet needs 
A European framework that supports the rapid 
and successful conduction of studies on phar-
maceutical compounds, medical devices and 
advanced therapies, using state-of-the-art as 
well as novel and innovative clinical studies 
methodology, would need to address the fol-
lowing issues: 
1. There is currently no platform at EU level 
where researchers can announce planned 
clinical studies and invite researchers from 
other EU countries to participate. 
2. It is difficult for academia to initiate multi-
national clinical trials. Clinical trials, in con-
trast to for example collecting real world 
data, are strongly regulated and involve a 
complex approval and implementation 
process. 
3. The current GDPR legislation does not 
provide a clear legal framework for ena-
bling cross-border sharing of sensitive 
data, and the merging of data from multi-
ple countries participating in a study is of-
ten delayed for reasons related to legal 
uncertainty and bureaucracy. There is for 
example interest in the academic commu-
nity to develop a European equivalent to 
the “UK biobank”2, but under the current 
rules that would be impossible.  
4. The existing Horizon 2020 programme 
does not provide a designated framework 
for the conduction of clinical studies, nor 
does it seem that this possibility will be of-
fered in the future under Horizon Europe. 
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Horizon 2020 has been adapted to better 
accommodate the implementation of clin-
ical studies, but it was not primarily de-
signed for this purpose. A designated 
framework would enable addressing the 
existing shortcomings and also take into 
account the specificities of these projects 
(such as the need for more flexible time-
lines and cost adjustments).  
5. There is a need to strengthen collabora-
tion between EU regulators and academia 
in the regulatory processes. The scientific 
community plays an important role in 
providing EU regulators such as the Euro-
pean Medicines Agency (EMA) with exper-
tise on the opportunities and challenges 
related to transformational research (such 
as novel clinical trial approaches, the use 
of real-world data, etc.) and in supporting 
the evaluation of increasingly complex 
medicines and trial designs taking into ac-
count legal, ethical, methodological and 
regulatory aspects.  
Suggested actions  
In light of the above-mentioned needs, we rec-
ommend the European Commission to: 
1. Create a platform where researchers from 
all EU countries can express an interest in 
joining multinational clinical studies. To 
this end, the Commission could consider 
expanding the scope of the existing EU 
study platforms where ongoing trials are 
already registered (EU Clinical Trials Reg-
ister3). Existing platforms where planned 
and ongoing clinical research is supported 
 
3 https://www.clinicaltrialsregister.eu/about.html  
4 https://ecrin.org/   
5 “A European Strategy for data”, COM(2020) 66 final, 
pp. 29-30. 
 
(such as ECRIN 4  - European Clinical Re-
search Infrastructure Network) could also 
be leveraged further for this purpose.   
2. Provide a simplified process, easier access 
and a more user-friendly interface to data-
bases such as EudraCT and Eudravigi-
lance, as this would greatly benefit investi-
gator-initiated clinical trials.   
3. Provide the swift adoption of guidelines 
and solve issues related to the interpreta-
tion of GDPR rules regarding the sharing 
of health data for scientific purposes. In 
this context, we welcome the proposal of 
the Commission to develop sector-specific 
legislative or non-legislative measures for 
a ”European health data space”, including 
a Code of Conduct for processing of per-
sonal data in the health sector, in accord-
ance with Article 40 of the GDPR5. We rec-
ommend that the Commission extensively 
consults and engages with the scientific 
community in implementing these actions, 
so that the future health data space will 
truly deliver on its ambition to support sci-
entific and medical research in Europe. 
4. Devote funding for the conduction of mul-
tinational clinical studies, via the Horizon 
Europe programme. The EU is the primary 
source of public funding for multinational 
collaborative research across borders 6 . 
Stepping up the EU’s support in this area 
is needed given the limited resources 
available for this kind of activities at Mem-
ber States’ level. In particular, we call on 
the European Commission to provide 
6 ”Building the future of health research. Proposal for a 
European Council for Health Research”, Scientific Panel 
for Health, May 2018, p. 20. https://ec.europa.eu/pro-
grammes/horizon2020/sites/horizon2020/files/build-
ing_the_future_of_health_research_sph_22052018_fi-
nal.pdf  
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additional funding for these studies within 
the Health Cluster of Pillar II.  
5. Use the opportunity offered by the Euro-
pean Medicines Agency’s (EMA) frame-
work for collaboration with academia7 to 
enhance a dialogue with the scientific 
community on emerging questions related 
to regulatory science. The definition of re-
search funding priorities in this area should 
also be based on the advice and the ex-
pertise of academia.   
 
A European framework for conducting multina-
tional clinical studies, including traditional ran-
domized trial designs, observational studies on 
large-scale biometric databases, and prag-
matic adaptive study approaches would con-
tribute to strengthen Europe’s position as a 
global leader in healthcare research. It would, 
in a wider perspective, help generate new 
knowledge both on novel pharmaceuticals, 
medical devices, and Advanced Therapy Me-
dicinal Products (ATMPs). Today, the existing 
challenges and obstacles can only be solved at 
the level of the EU.
 
 
7  https://www.ema.europa.eu/en/documents/regula-
tory-procedural-guideline/framework-collaboration-be-
tween-european-medicines-agency-academia_en.pdf  

